ストックスクリーナーアプリを入手
53.48
2.96%
1.54
アフターアワーズ：
53.30
-0.18
-0.34%
Bridgebio Pharma Inc (BBIO) 最新ニュース
Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
Pattern recognition hints at BridgeBio Pharma Inc. upsideForecast Cut & Long Hold Capital Preservation Tips - newser.com
How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockDollar Strength & Consistent Return Investment Signals - newser.com
Real time breakdown of BridgeBio Pharma Inc. stock performanceJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Market Overview & Weekly Market Pulse Updates - newser.com
How buybacks impact BridgeBio Pharma Inc. stock valueWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Is BridgeBio Pharma Inc a good long term investmentMarket Sentiment Surveys & Access Free Tools and Start Investing - earlytimes.in
What MACD and RSI say about BridgeBio Pharma Inc.Trade Entry Report & Verified Swing Trading Watchlist - newser.com
Why Is BridgeBio Stock Gaining Monday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga
Moss Adams Wealth Advisors LLC Has $1.04 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: A Biotech Powerhouse with a 32.50% Potential Upside - DirectorsTalk Interviews
BridgeBio Pharma Says Drug Reduced Death, Hospitalization in Cardiomyopathy Patients After 1 Month - MarketScreener
Will breakout in BridgeBio Pharma Inc. lead to full recovery2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
What analysts say about BridgeBio Pharma Inc stockEarnings Beat Highlights & Small Budget Investment Tips - earlytimes.in
BridgeBio (BBIO) Unveils Positive Results in ATTRibute-CM Study - GuruFocus
BridgeBio Pharma says Acoramidis reduces CVM or CVH risk by 49% through month 30 - MarketScreener
BridgeBio Pharma Reports Positive Results from ATTRibute-CM Study, Demonstrating Significant Reduction in Cardiovascular Outcomes with Acoramidis - Quiver Quantitative
53 Heart Events Prevented Per 100 Patients: BridgeBio's Acoramidis Shows Powerful Early Benefits in ATTR-CM - Stock Titan
What technical models suggest about BridgeBio Pharma Inc.’s comebackJuly 2025 Review & Consistent Income Trade Ideas - newser.com
BridgeBio Pharma Inc Stock Analysis and ForecastPortfolio Allocation Tips & Smart Beta Strategies That Actually Work - earlytimes.in
Best data tools to analyze BridgeBio Pharma Inc. stockStop Loss & Stepwise Swing Trade Plans - newser.com
H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) - MSN
Retirement Income Solutions Inc Acquires Shares of 5,000 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma’s Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism - Yahoo Finance
Atle Fund Management AB Grows Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Assenagon Asset Management S.A. Has $15.13 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Strs Ohio Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio to Present Additional Cardiovascular Outcomes - GlobeNewswire
BridgeBio Pharma to Present Key Clinical Trial Findings at Heart Failure Society of America Annual Scientific Meeting 2025 - Quiver Quantitative
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 - The Manila Times
New Cardiovascular Outcomes Data: BridgeBio's Acoramidis Shows Impact on ATTR-CM Patient Survival - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Biotech Powerhouse with 24% Upside Potential - DirectorsTalk Interviews
Risks To Shareholder Returns Are Elevated At These Prices For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - 富途牛牛
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Stock Position Lifted by Intech Investment Management LLC - MarketBeat
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
Fed Watch: Should value investors consider BridgeBio Pharma IncQuarterly Trade Report & Capital Efficient Trading Techniques - خودرو بانک
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Aug Mood: What is the Moat Score of BridgeBio Pharma IncWeekly Trade Analysis & Weekly Watchlist for Hot Stocks - خودرو بانک
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
2.95%
1.63%
大文字化:
|
ボリューム (24 時間):